Cerus Corporation (CERS) – What Are Researchers Thinking About This Stock?

Shares of Cerus Corporation (NASDAQ:CERS) have been given a consensus recommendation of “Hold” by the five research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $5.25.

CERS has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Cerus in a report on Monday, September 14th. Wall Street Zen raised shares of Cerus from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Finally, Freedom Broker began coverage on shares of Cerus in a research note on Thursday, August 20th. They issued a “buy” rating and a $6.50 price objective on the stock.

Insiders Place Their Bets

In related news, insider Chrystal Jensen sold 30,000 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $2.98, for a total value of $89,400.00. Following the transaction, the insider owned 936,657 shares in the company, valued at $2,791,237.86. The trade was a 3.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. StoneX Group Inc. bought a new stake in shares of Cerus during the 3rd quarter valued at about $33,000. Y Intercept Hong Kong Ltd bought a new stake in Cerus in the first quarter worth approximately $35,000. Focus Advisor Solutions LLC bought a new stake in Cerus in the third quarter worth approximately $35,000. Corient Private Wealth LP increased its holdings in Cerus by 48.6% in the second quarter. Corient Private Wealth LP now owns 15,064 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 4,926 shares in the last quarter. Finally, R Squared Ltd increased its holdings in Cerus by 62.6% in the third quarter. R Squared Ltd now owns 20,650 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 7,950 shares in the last quarter. 78.37% of the stock is owned by institutional investors.

Cerus Trading Up 2.3%

Shares of NASDAQ CERS traded up $0.04 during trading on Friday, reaching $1.99. The company had a trading volume of 1,821,444 shares, compared to its average volume of 2,358,073. The stock has a market cap of $400.87 million, a P/E ratio of -66.17 and a beta of 1.84. The company’s fifty day moving average price is $2.36 and its 200-day moving average price is $2.43. The company has a quick ratio of 1.15, a current ratio of 1.96 and a debt-to-equity ratio of 0.46. Cerus has a 12 month low of $1.47 and a 12 month high of $3.47.

Cerus Company Profile

Cerus Corporation is a biomedical products company focused on improving the safety of blood components used for transfusions. Its primary offering is the INTERCEPT Blood System, which uses a pathogen-reduction process designed to inactivate a broad range of viruses, bacteria, parasites and white blood cells in donated blood components. INTERCEPT is used to process platelet and plasma components. Cerus also develops related processing devices and supplies for blood centers and transfusion services.